

## News release

### **BioPheresis awarded grant "BioChance Plus-3" for the development of its new cancer treatment approach**

Heidelberg, Germany, October 2006 – BioPheresis GmbH has received a 2-year grant from the federal government for about 0.5 million Euros, to accelerate and expand the current and further work on a new cancer treatment with the company's OncoSorb® column.

This new approach of cancer therapy uses an immuno-adsorptive treatment with established apheresis procedures to combat metastatic cancers. By the application of an immuno-affinity (OncoSorb®) column soluble Tumor Necrosis Factor receptors (sTNFRs) and soluble Interleukine-2 alpha receptor (sIL-2Ra) were removed from patients' blood. Depletion of these immuno-inhibitory factors allows body's own immune response to attack and destroy tumors once again – as in a well working immune system, when TNF mediates destruction of transformed cells.

"Initial study data and the present decision of the German Federal Ministry of Education and Research indicate that our company and the OncoSorb® therapy have the potential to make a difference in the treatment of cancer patients." says CEO and Managing Director Dr. Bernhard Ehmer. "We look forward to obtain the CE-mark as the next step and are in the moment in the process of planning a study in metastatic breast cancer to generate more data to confirm the existing results."

#### **About BioPheresis**

BioPheresis' treatment for cancer originated from procedures discovered and developed by Dr. M. Rigdon Lentz. The Company's immunological therapeutic approach is based on data that specific inhibitors circulating in the blood retard or prevent an otherwise normal immune system from recognizing and destroying tumor cells. These inhibitors have been shown to be soluble Tumor Necrosis Factor receptors (sTNFRs) and to be overproduced in cancer patients. The BioPheresis technology removes these inhibiting sTNFRs and in addition the inhibiting soluble receptor Interleukine-2 alpha (sIL-2Ra).

Filing is in process for a CE (Conformité Européenne) Mark in Europe for the OncoSorb® column and a further clinical trial in recurrent metastatic breast cancer is planned to begin in Europe in 2007. BioPheresis also plans discussions with the FDA in 2007 to resume the clinical and regulatory approval process in the United States.

The Company has a number of patents issued in the United States, Europe and other countries. Other patent applications are pending both internationally and in the US. In 2005 a 6,5 Million Euro Series A preferred stock financing with Scandinavian Life Science Venture (SLS), Stockholm and First Ventury, Heidelberg was completed.

**Contact:** BioPheresis GmbH, Henry Edmunds +49 (0)6221 / 618 91 02  
Logo: [www.biopheresis.de/layout](http://www.biopheresis.de/layout)